Competition hurdles vanish as Curaleaf clears reviews for its Aurora Cannabis takeover, setting up a Dec. 4 deadline for shareholders.
Curaleaf Gains Competition Clearance
Canada’s Competition Bureau issued a no‑action letter on Nov. 2, and Germany’s Federal Cartel Office cleared the deal on Nov. 3, according to Curaleaf’s Nov. 10 announcement. The bureau’s interim commissioner signaled no intent to invoke section 92 of the Competition Act, allowing the all‑share purchase of Aurora (ACB) to proceed toward its Dec. 4 expiry.
Curaleaf, a U.S.‑based cannabis producer and retailer with a global supply chain, says the decisions complete the required competition reviews in Canada and Germany, the only jurisdictions that needed clearance, though final conditions remain.
Bid Terms and Share Prices
Curaleaf’s October 6 proposal offers $1 in cash plus 0.4013 Curaleaf shares per Aurora share, capped at $6 of total value per share, exposing the stock component to Curaleaf price swings. Aurora closed at C$7.30 on Nov. 9, while Curaleaf traded at C$12.68 on the TSX.
Organigram’s competing deal, announced Nov. 3, values Aurora at roughly C$561 million with an all‑share exchange of 5.8626 Organigram shares per Aurora share, representing C$3.75 plus the Organigram equity portion, subject to proration.
International Scale and Cost Savings
Curaleaf’s website, accessed Nov. 10, projects at least $40 million in overhead, procurement and supply‑chain savings, emphasizing continued shareholder ownership and diversification across its international operations.
The Organigram‑Aurora partnership highlighted five European‑certified production and distribution facilities and more than C$50 million in synergies from procurement, distribution, public‑company costs and cross‑selling, supporting a combined Canadian recreational and global medical business.
Board Support and Outlook
Aurora’s board unanimously endorsed Organigram’s offer and rejected Curaleaf’s revised bid, according to the joint release. Curaleaf chair and CEO Boris Jordan said, “With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides.”
